CC-Chemokine Ligand 18 Is an Independent Prognostic Marker in Lymph Node-positive Non-small Cell Lung Cancer

Schmid, Severin; Csanádi, Ágnes; Kozhuharov, Nikola; Tchudjin, Marceau; Kayser, Claudia; Rawluk, Justyna; Passlick, Bernward; Werner, Martin; Prasse, Antje; Kayser, Gian

doi:10.21873/anticanres.12676

Cited by 7 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An increased level of CCL18 in colorectal cancer [43] and gastric adenocarcinoma [44] is associated with a better prognosis. In non-small cell lung cancer, a greater infiltration of CCL18-producing cells is associated with a better prognosis [183], although the level of this chemokine in the plasma of patients with this type of cancer is associated with a worse prognosis [175] (Table 1). Nevertheless, the data in the Human Protein Atlas (https://www.proteinatlas.org) on the level of mRNA for CCL18 in tumors of various cancers do not confirm a clear relationship between an increased CCL18 expression and a worse survival [184,185] (Table 2).…”

Section: Ccl18 As a Tumor Markermentioning

confidence: 99%

CCL18 in the Progression of Cancer

Korbecki

Olbromski

Dzięgiel

2020

IJMS

View full text Add to dashboard Cite

A neoplastic tumor consists of cancer cells that interact with each other and non-cancerous cells that support the development of the cancer. One such cell are tumor-associated macrophages (TAMs). These cells secrete many chemokines into the tumor microenvironment, including especially a large amount of CCL18. This chemokine is a marker of the M2 macrophage subset; this is the reason why an increase in the production of CCL18 is associated with the immunosuppressive nature of the tumor microenvironment and an important element of cancer immune evasion. Consequently, elevated levels of CCL18 in the serum and the tumor are connected with a worse prognosis for the patient. This paper shows the importance of CCL18 in neoplastic processes. It includes a description of the signal transduction from PITPNM3 in CCL18-dependent migration, invasion, and epithelial-to-mesenchymal transition (EMT) cancer cells. The importance of CCL18 in angiogenesis has also been described. The paper also describes the effect of CCL18 on the recruitment to the cancer niche and the functioning of cells such as TAMs, regulatory T cells (Treg), cancer-associated fibroblasts (CAFs) and tumor-associated dendritic cells (TADCs). The last part of the paper describes the possibility of using CCL18 as a therapeutic target during anti-cancer therapy.

show abstract

Section: Ccl18 As a Tumor Markermentioning

confidence: 99%

CCL18 in the Progression of Cancer

Korbecki

Olbromski

Dzięgiel

2020

IJMS

View full text Add to dashboard Cite

show abstract

“…An increased level of CCL18 in colorectal cancer and gastric adenocarcinoma is associated with a better prognosis. In non-small cell lung cancer, a greater infiltration of CCL18-producing cells is associated with a better prognosis [52], although the level of this chemokine in the plasma of patients with this type of cancer is associated with a worse prognosis. Since CCL18 has been demonstrated to be released by TAMs which play important roles in malignant diseases, CCL18 has been increasingly considered to be involved in the pathogenesis and progress of various cancers.…”

Section: Discussionmentioning

confidence: 99%

The potential value of some adipokines and cytokines as diagnostic biomarkers for prostate cancer

Yousif,

Ismail

2023

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

Background: The role of Adipokines and proinflammatory cytokines is said to be crucial in the development of prostate cancer. Vaspin, Chemerin, Omentin, Interleukins IL-1β, interleukin-8 (IL8), Colony-stimulating factor (GM-CSF) and CC chemokine ligand 18 (CCL18) have all been proven to take part in tumor growth and progression. Aim of the study: The study aimed to explore circulating novel adipocytokines, such as serum of Vaspin, Chemerin and Omentin levels in patients with prostate cancer and to determine the level of selected proinflammatory cytokines (CCL18, IL-8, IL1, and GM-CSF). Methods: Three groups were included in the current study: Group (1) :32 patients with metastatic prostate cancer who received chemotherapy, Group (2): 30 untreated patients with nonmetastatic prostate cancer, and Group (3): 30 healthy controls. ELISA technique was used to assess serum levels of Vaspin, Chemerin, Omentin, CCL18, IL-8, IL1, and GM-CSF). Results: The Prostate cancer group exhibited higher serum levels of Vaspin, Chemerin, Omentin, CCL18, IL-8, IL1, and GM-CSF compared to the control group. Chemotherapy-treated patients exhibited significantly increased levels of the pro-inflammatory cytokines (IL-8) and Adipokines (Vaspin and Omentin) and decreased levels of the pro-inflammatory cytokines (IL-1) and Adipokines (Chemerin). The correlation analysis showed a significant positive correlation of serum Chemerin with Vaspin (r = 0.957, p-value<0.0001), IL-8 (r = 0.9475, p-value < 0.0001) and IL-1β (r = 0.7771, p-value < 0.0029). Omentin and GS-CSF levels showed a non-significant positive correlation with Chemerin level (r = 0.1259; p = 0.6967).) and (r = 0.4247; p = 0.1688), respectively. While significant negative correlation was found between (Chemerin) with CCL-18 (r = –0.7916, p = 0.0022), serum Vaspin was significantly and negatively correlated with the levels of CCL-18 (r = –0.9349, p < 0.0001), whereas there was a significant positive correlation between Vaspin level with IL-8 (R=0.9995, p <0.0001); IL-1β(r = 0.561, p = 0.0057). The data demonstrated that Vaspin was positively and non-significantly correlated with the level of GS-CSF (r = 0.1437, p =0.656); serum Omentin was significantly and negatively correlated with the levels of GS-CSF (r = –0.8447, p = 0.0005), and CCL-18 (r= –0.7058, p = 0.0103), whereas there was a non-significant positive correlation between Omentin level with IL-8 (r = 0.4364, p = 0.1561). The data demonstrated that Omentin was negatively and non-significantly correlated with the level of IL-1β (r= –0.5366, p =0.0786). Conclusions: This study indicated increased levels of serum Vaspin, Chemerin, Omentin, Interleukins IL-1β, interleukin-8 (IL8), Colony-stimulating factor (GM-CSF) and CC chemokine ligand 18 (CCL18) in patients with Prostate cancer. These findings suggest that the cytokines, and adipokines, whose levels were elevated in the chemotherapy-treated patients may be involved in the pathophysiology of prostate cancer. Vaspin, Chemerin and Omentin might play an important role in Prostate cancer progression through their association with Adipokines and proinflammatory cytokines. More studies are needed to investigate the possible role of Vaspin, Chemerin and Omentin as potential markers in the development of Prostate cancer.

show abstract

“…In lung cancer, the chemokine CCL18 ligand is highly expressed in M2 macrophages. Schmid et al 84 showed that a higher proportion of TAMs positives to CCL18 was related to a shorter survival rate by survival analysis; thus, this chemokine could be used as a prognosis biomarker. Schmid et al 85 showed that elevated CCL18 levels are related to tumor size and poor prognosis in the NSCLC tumor microenvironment; moreover, this work also highlighted that serum levels of CCL18 were not related to either tumor size or prognosis.…”

Section: Immunological Approach and Biomarkers For Cancer Diseasementioning

confidence: 99%

A Quest for New Cancer Diagnosis, Prognosis and Prediction Biomarkers and Their Use in Biosensors Development

Ramírez-Valles

Rodríguez-Pulido

Barraza-Salas

et al. 2020

Technol Cancer Res Treat

View full text Add to dashboard Cite

Traditional techniques for cancer diagnosis, such as nuclear magnetic resonance, ultrasound and tissue analysis, require sophisticated devices and highly trained personnel, which are characterized by elevated operation costs. The use of biomarkers has emerged as an alternative for cancer diagnosis, prognosis and prediction because their measurement in tissues or fluids, such as blood, urine or saliva, is characterized by shorter processing times. However, the biomarkers used currently, and the techniques used for their measurement, including ELISA, western-blot, polymerase chain reaction (PCR) or immunohistochemistry, possess low sensitivity and specificity. Therefore, the search for new proteomic, genomic or immunological biomarkers and the development of new noninvasive, easier and cheaper techniques that meet the sensitivity and specificity criteria for the diagnosis, prognosis and prediction of this disease has become a relevant topic. The purpose of this review is to provide an overview about the search for new cancer biomarkers, including the strategies that must be followed to identify them, as well as presenting the latest advances in the development of biosensors that possess a high potential for cancer diagnosis, prognosis and prediction, mainly focusing on their relevance in lung, prostate and breast cancers.

show abstract

CC-Chemokine Ligand 18 Is an Independent Prognostic Marker in Lymph Node-positive Non-small Cell Lung Cancer

Abstract: In advanced lung adenocarcinoma, infiltration of CCL18 TAMs was increased and higher expression of CCL18 by TAMs was associated with a favorable prognosis in lymph-node positive NSCLC.

Cited by 7 publications

References 30 publications

CCL18 in the Progression of Cancer

CCL18 in the Progression of Cancer

The potential value of some adipokines and cytokines as diagnostic biomarkers for prostate cancer

A Quest for New Cancer Diagnosis, Prognosis and Prediction Biomarkers and Their Use in Biosensors Development

Contact Info

Product

Resources

About